Cargando…
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018764/ https://www.ncbi.nlm.nih.gov/pubmed/35440099 http://dx.doi.org/10.1038/s41408-022-00659-9 |
_version_ | 1784689099169333248 |
---|---|
author | Kleinstern, Geffen Larson, Dirk R. Allmer, Cristine Norman, Aaron D. Muntifering, Grace Sinnwell, Jason Visram, Alissa Rajkumar, Vincent Dispenzieri, Angela Kyle, Robert A. Slager, Susan L. Kumar, Shaji Vachon, Celine M. |
author_facet | Kleinstern, Geffen Larson, Dirk R. Allmer, Cristine Norman, Aaron D. Muntifering, Grace Sinnwell, Jason Visram, Alissa Rajkumar, Vincent Dispenzieri, Angela Kyle, Robert A. Slager, Susan L. Kumar, Shaji Vachon, Celine M. |
author_sort | Kleinstern, Geffen |
collection | PubMed |
description | Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m(2) < 25/≥25) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI ≥ 25 versus BMI < 25 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0–25), while 465 patients died and 57 progressed and developed MM (N = 39), AL amyloidosis (N = 8), lymphoma (N = 5), or Waldenstrom-macroglobulinemia (N = 5). In univariate analyses, BMI ≥ 25 (HR = 2.14,CI:1.05–4.36, P = 0.04), non-IgG (HR = 2.84, CI:1.68–4.80, P = 0.0001), high monoclonal (M) protein (HR = 2.57, CI:1.50–4.42, P = 0.001), and abnormal free light chain ratio (FLC(r)) (HR = 3.39, CI:1.98–5.82, P < 0.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic = 0.75, CI:0.68–0.82). The BMI association was stronger among females (HR = 3.55, CI:1.06–11.9, P = 0.04) vs. males (HR = 1.39, CI:0.57–3.36, P = 0.47), although the interaction between BMI and sex was not significant (P = 0.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLC(r). This association may be stronger among females. |
format | Online Article Text |
id | pubmed-9018764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90187642022-04-28 Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota Kleinstern, Geffen Larson, Dirk R. Allmer, Cristine Norman, Aaron D. Muntifering, Grace Sinnwell, Jason Visram, Alissa Rajkumar, Vincent Dispenzieri, Angela Kyle, Robert A. Slager, Susan L. Kumar, Shaji Vachon, Celine M. Blood Cancer J Article Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m(2) < 25/≥25) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI ≥ 25 versus BMI < 25 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0–25), while 465 patients died and 57 progressed and developed MM (N = 39), AL amyloidosis (N = 8), lymphoma (N = 5), or Waldenstrom-macroglobulinemia (N = 5). In univariate analyses, BMI ≥ 25 (HR = 2.14,CI:1.05–4.36, P = 0.04), non-IgG (HR = 2.84, CI:1.68–4.80, P = 0.0001), high monoclonal (M) protein (HR = 2.57, CI:1.50–4.42, P = 0.001), and abnormal free light chain ratio (FLC(r)) (HR = 3.39, CI:1.98–5.82, P < 0.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic = 0.75, CI:0.68–0.82). The BMI association was stronger among females (HR = 3.55, CI:1.06–11.9, P = 0.04) vs. males (HR = 1.39, CI:0.57–3.36, P = 0.47), although the interaction between BMI and sex was not significant (P = 0.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLC(r). This association may be stronger among females. Nature Publishing Group UK 2022-04-19 /pmc/articles/PMC9018764/ /pubmed/35440099 http://dx.doi.org/10.1038/s41408-022-00659-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kleinstern, Geffen Larson, Dirk R. Allmer, Cristine Norman, Aaron D. Muntifering, Grace Sinnwell, Jason Visram, Alissa Rajkumar, Vincent Dispenzieri, Angela Kyle, Robert A. Slager, Susan L. Kumar, Shaji Vachon, Celine M. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota |
title | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota |
title_full | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota |
title_fullStr | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota |
title_full_unstemmed | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota |
title_short | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota |
title_sort | body mass index associated with monoclonal gammopathy of undetermined significance (mgus) progression in olmsted county, minnesota |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018764/ https://www.ncbi.nlm.nih.gov/pubmed/35440099 http://dx.doi.org/10.1038/s41408-022-00659-9 |
work_keys_str_mv | AT kleinsterngeffen bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT larsondirkr bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT allmercristine bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT normanaarond bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT muntiferinggrace bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT sinnwelljason bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT visramalissa bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT rajkumarvincent bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT dispenzieriangela bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT kyleroberta bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT slagersusanl bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT kumarshaji bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota AT vachoncelinem bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota |